Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 401–500 of 1,001
Sears, B., & Ricordi, C. (2012) · PubMed · Cited by 75
Drug Management of Obesity — Efficacy versus Safety
Astrup, A. V. (2010) · New England Journal of Medicine · doi:10.1056/nejme1004076 · Cited by 53
Valvular heart disease associated with fenfluramine-phentermine.
Kurz, X., & Ermen, A. V. (1997) · PubMed · Cited by 53
Tratamento Farmacológico da Obesidade
Mancini, M. C., & Halpern, A. (2002) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302002000500003 · Cited by 84
Drug-induced valvular heart disease
Cosyns, B., Droogmans, S., Rosenhek, R., & Lancellotti, P. (2012) · Heart · doi:10.1136/heartjnl-2012-302239 · Cited by 54
Townsend, T. A., Wrana, J. L., Davis, G. E., & Barnett, J. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710607200 · Cited by 55
Psychiatric medication‐induced obesity: treatment options
Schwartz, T. L., Nihalani, N. D., Virk, S., Jindal, S., & Chilton, M. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00149.x · Cited by 58
Donnelly, K. B. (2008) · Toxicologic Pathology · doi:10.1177/0192623307312707 · Cited by 55
“In 1997, the first report of heart valve disease in patients taking the combination was published (Connolly et al 1997).”
BackgroundAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 53
Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
Valentino, M. A., Lin, J. E., & Waldman, S. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.57 · Cited by 59
Roberto, C. A., Pomeranz, J. L., & Fisher, J. O. (2014) · Journal of Consumer Psychology · doi:10.1016/j.jcps.2014.03.001 · Cited by 55
“…medications can produce comparably modest weight loss (Glazer, 2001; Yanovski & Yanovski, 2002), but many of these drugs have been taken off the market for serious side effects (Connolly et al., 1997) or have side effects that greatly reduce adherence (Ecinosa, Bernard, Steiner, & Chen, 2005).”
BackgroundSafety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 51
Role of serotonin in body weight, insulin secretion and glycaemic control
Georgescu, T. R., Lyons, D. J., & Heisler, L. K. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12960 · Cited by 51
Including elderly people in clinical trials
Avorn, J. (1997) · BMJ · doi:10.1136/bmj.315.7115.1033 · Cited by 51
“However, here too most nations fail to encourage a coherent, robust response. Insights about important, even life threatening, side effects are too often left to arise from ad hoc observations by alert practitioners, rather than through any proactive method of public sector surveillance.”
BackgroundGenetics and pathophysiology of mitral valve prolapse
Delwarde, C., Capoulade, R., Mérot, J., Scouarnec, S. L., Bouatia‐Naji, N., Yu, M., Huttin, O., Selton‐Suty, C., Sellal, J., Piriou, N., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1077788 · Cited by 50
“Serotonin receptor (5-HTR) agonist drugs, such as benfluorex (Mediator R ), stimulate serotonergic pathways leading to valve degeneration with increased VICs proliferation, endocardial damage and ECM accumulation (76).”
BackgroundFailure to use new breakthrough treatments for epilepsy
Klein, P., Krauss, G. L., Steinhoff, B. J., Devinsky, O., & Sperling, M. R. (2023) · Epilepsia · doi:10.1111/epi.17564 · Cited by 51
The Sympathetic Innervation of Adipose Tissues: Regulation, Functions, and Plasticity
Willows, J. W., Blaszkiewicz, M., & Townsend, K. L. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220030 · Cited by 55
Smith, S. R., O'Neil, P. M., Astrup, A., Finer, N., Sanchez‐Kam, M., Fraher, K., Fain, R., & Shanahan, W. R. (2014) · Obesity · doi:10.1002/oby.20841 · Cited by 49
Dingerkus, V. L. S., Gaber, T. J., Helmbold, K., Bubenzer, S., Eisert, A., Sánchez, C. L., & Zepf, F. D. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0793-z · Cited by 47
Hajjo, R., Grulke, C., Golbraikh, A., Setola, V., Huang, X., Roth, B. L., & Tropsha, A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100600y · Cited by 51
Pharmacotherapy for obesity: What you need to know
Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16094 · Cited by 46
Effects of Caffeine on Brown Adipose Tissue Thermogenesis and Metabolic Homeostasis: A Review
Schaik, L. V., Kettle, C., Green, R., Irving, H. R., & Rathner, J. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.621356 · Cited by 55
“Sympathomimetic agonist Valvular disease (Connolly et al., 1997; Teramae et al., 2000).”
The Year in Valvular Heart Disease
Rahimtoola, S. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.022 · Cited by 50
Appetite suppressants and valvular heart disease – a systematic review
Loke, Y. K., Derry, S., & Pritchard-Copley, A. (2002) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-2-6 · Cited by 50
Golomb, B. A., Criqui, M. H., White, H., & Dimsdale, J. E. (2004) · Controlled Clinical Trials · doi:10.1016/j.cct.2003.08.014 · Cited by 52
Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction
ROTHMAN, R. B., ELMER, G. I., SHIPPENBERG, T. S., REA, W., & BAUMANN, M. H. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08222.x · Cited by 49
Weir, Ε. K., Reeve, H. L., Johnson, G. J., Michelakis, E. D., Nelson, D. P., & Archer, S. L. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.200s · Cited by 50
Off-Label Use vs Off-Label Marketing of Drugs
Van Norman, G. A. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.12.011 · Cited by 49
“After an article was published describing dramatic weight loss if they were used off-label in combination, doctors began prescribing the drugs together, and sales eventually reached over 18 million prescriptions annually in the United States.19 Shortly thereafter, it was discovered that almost one-third of patients wh…”
MethodRouaud, A., Calder, A. E., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231225609 · Cited by 53
Crisafulli, S., Bate, A., Brown, J. S., Candore, G., Chandler, R. E., Hammad, T. A., Lane, S., Maro, J. C., Norén, G. N., Pariente, A., et al. (2025) · Drug Safety · doi:10.1007/s40264-025-01548-3 · Cited by 52
The use of serotonergic drugs to treat obesity – is there any hope?
Bello, N. T., & Liang, N.-C. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s11859 · Cited by 62
The safety of pharmacologic treatment for pediatric obesity
Chao, A. M., Wadden, T. A., & Berkowitz, R. I. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1437143 · Cited by 52
Serum Serotonin Concentrations in Dogs with Degenerative Mitral Valve Disease
Arndt, J. W., Reynolds, C., Singletary, G. E., Connolly, J. M., Levy, R. J., & Oyama, M. A. (2009) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2009.0378.x · Cited by 49
Serotonin Transporter Mechanisms and Cardiac Disease
Levy, R. J. (2006) · Circulation · doi:10.1161/circulationaha.105.593459 · Cited by 53
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment
Hong, W., Haviland, I., Pestana‐Knight, E., Weisenberg, J. L. Z., Demarest, S., Marsh, E. D., & Olson, H. E. (2022) · CNS Drugs · doi:10.1007/s40263-022-00921-5 · Cited by 50
“Fenfluramine is a serotonergic agent originally developed as an appetite suppressant in combination with phentermine but was withdrawn from the market in 1997 because of complications related to valvular heart disease [63].”
BackgroundNEURAL AND CARDIAC TOXICITIES ASSOCIATED WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)
Baumann, M., & Rothman, R. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)88010-0 · Cited by 46
Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin‐A1
Frieden, L. A., Townsend, T. A., Vaught, D., DeLaughter, D. M., Hwang, Y., Barnett, J. V., & Chen, J. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22458 · Cited by 51
Balachandran, K., Bakay, M. A., Connolly, J. M., Zhang, X., Yoganathan, A. P., & Levy, R. J. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.03.084 · Cited by 53
Schoonjans, A.-S., Marchau, F., Paelinck, B. P., Lagae, L., Gammaitoni, A., Pringsheim, M., Keane, M. G., & Ceulemans, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1355781 · Cited by 46
Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Mathew, H., Paschou, S. A., Perakakis, N., Koniaris, A., Kelesidis, T., & Mantzoros, C. S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13655 · Cited by 47
“therapy has often been challenging because of issues related to cardiovascular safety.(3) Conversely, it was recently demonstrated that”
BackgroundLai, W. W., Galer, B. S., Wong, P. C., Farfel, G. M., Pringsheim, M., Keane, M. G., & Agarwal, A. (2020) · Epilepsia · doi:10.1111/epi.16638 · Cited by 52
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Carabello, B. A. (1998) · Current Problems in Cardiology · doi:10.1016/s0146-2806(98)80005-4 · Cited by 48
Metabolic actions of hypothalamic SIRT1
Coppari, R. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.01.002 · Cited by 47
Serotonin and catecholamines in the development and progression of heart valve diseases
Goldberg, E., Grau, J. B., Fortier, J. H., Salvati, E., Levy, R. J., & Ferrari, G. M. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx092 · Cited by 48
Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy
Samanta, D. (2022) · Children · doi:10.3390/children9081159 · Cited by 58
Sohn, J.-W., & Williams, K. W. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8240-6 · Cited by 45
Hsiao, A., Santucci, K., Seo-Mayer, P., Mariappan, M. R., Hodsdon, M., Banasiak, K., & Baum, C. (2005) · Clinical Toxicology · doi:10.1081/clt-200058946 · Cited by 46
Tramadol Overdose and Serotonin Syndrome Manifesting as Acute Right Heart Dysfunction
Garrett, P. (2004) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0403200417 · Cited by 47
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin
Rothman, R. B., Redmon, J. B., Raatz, S. K., Kwong, C. A., Swanson, J. E., & Bantle, J. P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00896-6 · Cited by 47
Curfman, G. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370909 · Cited by 46
Auguste, E. E., Bowdring, M. A., Kasparek, S. W., McPhee, J., Tabachnick, A. R., Tung, I., (SEED), S. F. E. E. A. D., & Galán, C. A. (2023) · Perspectives on Psychological Science · doi:10.1177/17456916221141374 · Cited by 51
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 48
Long-term serotonin effects in the rat are prevented by terguride
Hauso, Ø., Gustafsson, B. I., Loennechen, J. P., Stunes, A. K., Nordrum, I. S., & Waldum, H. L. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.009 · Cited by 46
Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases
Cohen, P. A. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0878-4 · Cited by 46
Regulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 57
Turner, N. C., & Clapham, J. C. (1998) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8845-5_2 · Cited by 65
Pinborg, L. H., Adams, K. H., Yndgaard, S., Hasselbalch, S. G., Holm, S., Kristiansen, H., Paulson, O. B., & Knudsen, G. M. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000126233.08565.e7 · Cited by 46
Connolly, H. M., & McGoon, M. D. (1999) · Current Problems in Cardiology · doi:10.1016/s0146-2806(99)90013-0 · Cited by 49
Self-citationRisks of Coronary Heart Disease in Women: Current Understanding and Evolving Concepts
Tsang, T. S. M., Barnes, M. E., Gersh, B. J., & Hayes, S. N. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.12.1289 · Cited by 51
A Risk-Benefit Assessment of Anti-Obesity Drugs
Kolanowski, J. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00003 · Cited by 50
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 55
Molan, A. L., Lila, M. A., & Mawson, A. J. (2007) · Food Chemistry · doi:10.1016/j.foodchem.2007.09.018 · Cited by 45
“Berry fruits contain wide range of bioactive compounds, such as phenolics, organic acids and anthocyanins which have antimicrobial activities against human pathogens (Puupponen-Pimia ¨ et al., 2001, 2005) and antioxidant activity ( Cao et al., 1998 ).”
BackgroundCavero, I., & Guillon, J. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.12.004 · Cited by 46
“Pergolide and fenfluramine (of which (+)-norfenfluramine is the active metabolite) as already mentioned, have been withdrawn from the market because they cause serious valvular disease (Andrejak & Tribouilloy, 2013; Connolly et al., 1997; Rothman & Baumann, 2009; Seferian et al., 2013).”
BackgroundInfluentialLeptin and the treatment of obesity: its current status
Lee, D. W., Leinung, M. C., Rozhavskaya-Arena, M., & Grasso, P. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01424-3 · Cited by 57
Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat.
Yuen, Y. P., Lai, C.-K., Poon, W., Ng, S. W., Chan, A. Y. W., & Mak, T. W. L. (2007) · PubMed · Cited by 58
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-Related Diseases
Swanson, H. I., Wada, T., Xie, W., Renga, B., Zampella, A., Distrutti, E., Fiorucci, S., Kong, B., Thomas, A., Guo, G. L., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048694 · Cited by 47
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
Vilhelmsson, A., Davis, C., & Mulinari, S. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001945 · Cited by 45
The chiral switch: the development of single enantiomer drugs from racemates.
Hutt, A. J., & Valentová, J. (2003) · Research Portal (King's College London) · Cited by 45
Koncz, D., Tóth, B., Roza, O., & Csupor, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.611361 · Cited by 38
Sumińska, M., Podgórski, R., Bogusz‐Górna, K., Skowrońska, B., Mazur, A., & Fichna, M. (2022) · Obesity Reviews · doi:10.1111/obr.13440 · Cited by 52
Vascular actions of MDMA involve α1 and α2‐adrenoceptors in the anaesthetized rat
McDaid, J., & Docherty, J. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704094 · Cited by 45
“Certainly, chronic use of methamphetamine may also result in serious cardiovascular changes in man including tachycardia and palpitations (Chan et al., 1994), and another amphetamine derivative, fen¯uramine, has been linked to valvular heart disease (Connolly et al., 1997).”
BackgroundValvular Heart Disease in Patients Taking Pergolide
Waller, E. A., Kaplan, J., & Heckman, M. G. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1016 · Cited by 47
Resectional gastric bypass is a new alternative in morbid obesity
Curry, T. K., Carter, P. L., Porter, C. A., & Watts, D. M. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(98)00050-6 · Cited by 45
Steiger, M. J., Jost, W. H., Grandas, F., & Camp, G. V. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0179-4 · Cited by 48
Echocardiography in the Era of Obesity
Hajj, M. C. E., & Litwin, S. E. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.03.009 · Cited by 46
Smith, S. A., Waggoner, A. D., Fuentes, L. D. L., & Dávila‐Román, V. G. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2009.05.002 · Cited by 44
Elangbam, C. S., Lightfoot, R. M., Yoon, L., Creech, D., Geske, R. S., Crumbley, C. W., Gates, L. D., & Wall, H. G. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6500.2005 · Cited by 46
“…VHD in humans with carcinoid tumors and use of 5HT2B agonists such as fenfluramine, dexfenfluramine, ergotamine, dihydroergotamine, methysergide (Connolly et al. 1997; Jick et al. 1998; Fitzgerald et al. 2000; Rothman et al. 2000; Rajamannan et al. 2001; Weissman 2001; Nebigil and Maroteaux…”
BackgroundThe Fen‐Phen Finale: A Study of Weight Loss and Valvular Heart Disease
Wadden, T. A., Berkowitz, R. I., Silvestry, F. E., Vogt, R. A., Sutton, M. G. S. J., Stunkard, A. J., Foster, G. D., & Aber, J. L. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00350.x · Cited by 47
5‐HT 2C receptor modulation and the treatment of obesity
Bickerdike, M. J., Vickers, S. P., & Dourish, C. T. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00037.x · Cited by 44
Septic Pulmonary Embolism Associated With Periodontal Disease
Shiota, Y., Arikita, H., Horita, N., Hiyama, J., Ono, T., Ohkawa, S., & Yamakido, M. (2002) · CHEST Journal · doi:10.1378/chest.121.2.652 · Cited by 44
Cannistra, L. B., & Cannistra, A. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391112 · Cited by 44
Weissman, N. J., Panza, J. A., Tighe, J. F., & Gwynne, J. T. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00009 · Cited by 44
Baumann, M. H., AYESTAS, M. A., & Rothman, R. B. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-21-09069.1998 · Cited by 44
“Recently, racemic FEN and D-FEN have been withdrawn from clinical use because of the occurrence of cardiac valve abnormalities in some patients ( Connolly et al., 1997 ).”
BackgroundPathology of inflammatory native valvular heart disease
Veinot, J. P. (2006) · Cardiovascular Pathology · doi:10.1016/j.carpath.2006.04.007 · Cited by 47
Smith, S. R., Garvey, W. T., Greenway, F. L., Zhou, S., Fain, R., Pilson, R., Fujioka, K., & Aronne, L. J. (2017) · Obesity · doi:10.1002/oby.21811 · Cited by 42
Ayme‐Dietrich, E., Lawson, R., Côté, F., de Tapia, C., Silva, S. D., Ebel, C., Hechler, B., Gachet, C., Guyonnet, J., Rouillard, H., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13981 · Cited by 49
Baumann, M. H., Bulling, S., Benaderet, T. S., Saha, K., AYESTAS, M. A., Partilla, J. S., Ali, S. F., Stockner, T., Rothman, R. B., Sandtner, W., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.331 · Cited by 45
Appetite Suppressants and Valvular Heart Disease
Weissman, N. J. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200104000-00008 · Cited by 43
Guías de práctica clínica de la Sociedad Española de Cardiología en valvulopatías
Azpitarte, J., Alonso, Á. M., Gallego, F. G., González‐Santos, J. M., Paré, C., & Tello, A. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75227-4 · Cited by 64
Halpern, B., & Mancini, M. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 41
Strzelczyk, A., Pringsheim, M., Mayer, T., Polster, T., Klotz, K. A., Muhle, H., Alber, M., Trollmann, R., Spors, H., Kluger, G. J., et al. (2021) · Epilepsia · doi:10.1111/epi.17034 · Cited by 43
Dopamine/serotonin releasers as medications for stimulant addictions
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00919-9 · Cited by 47
“, 1988), investigators initially speculated that serotonergic mechanisms might contribute to VHD (Connolly et al., 1997; Connolly and McGoon, 1999).”
BackgroundPatterns of drug-induced cardiovascular pathology in the beagle dog: relevance for humans
Greaves, P. (1998) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(98)80008-0 · Cited by 42
Pharmacological Approaches for the Treatment of Obesity
Fern??ndez-L??pez, J.-A., Remesar, X., Foz, M., & Alemany, M. (2002) · Drugs · doi:10.2165/00003495-200262060-00005 · Cited by 45
Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04155.x · Cited by 45
Aortic and Mitral Fenfluramine-Phentermine Valvulopathy in 64 Patients Treated With Anorectic Agents
Volmar, K. E., & Hutchins, G. M. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-1555-aamfpv · Cited by 44
Arterburn, D. E., & Noël, P. H. (2001) · BMJ · doi:10.1136/bmj.322.7299.1406 · Cited by 51
Mutations in Melanocortin-3 Receptor Gene and Human Obesity
Yang, Z., & Tao, Y. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.01.002 · Cited by 43
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.